Innocan Pharma Corporation (TSE:INNO) has released an update.
Innocan Pharma’s recent study suggests its LPT-CBD platform could revolutionize treatment for neurological disorders, with a proven ability to release CBD into the bloodstream for extended periods and penetrate the brain. Additionally, the company is advancing with a private placement of up to 12 million units to raise C$3 million for corporate purposes. This financial move underlines Innocan’s commitment to furthering its pharmaceutical technology and consumer wellness segments.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
